Biologic innovation is transforming the Cosentyx Drug Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Cosentyx Drug Market By The End Of 2030?

The cosentyx drug market has shown substantial growth over recent years. Its valuation is projected to rise from $5.68 million in 2025 to $6.21 million in 2026, representing a compound annual growth rate (CAGR) of 9.2%. This historical expansion is attributable to various factors such as the approval of il 17 inhibitors, the significant prevalence of psoriasis and arthritis, a limited response to tnf inhibitors, specialist dermatology adoption, and the implementation of biologic treatment guidelines.

The Cosentyx drug market is projected to experience robust expansion over the coming years. It is anticipated to reach $8.74 million by 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast timeframe is primarily driven by factors such as the rise in autoimmune disease diagnoses, the broadening of treatment applications, heightened patient consciousness, enhanced access to biologics, and supportive long-term efficacy data. Key trends expected throughout this period encompass the increasing acceptance of IL-17 inhibitor treatments, the wider application across various autoimmune conditions, a move towards targeted biologic therapies, greater utilization of long-term maintenance regimens, and a growing call for self-injectable biologics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19891&type=smp

What Drivers Are Shaping The Future Growth Of The Cosentyx Drug Market?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the Cosentyx market in the future. These conditions are defined by the immune system incorrectly attacking the body’s own healthy cells and tissues. The growing incidence of autoimmune diseases stems from genetic factors, environmental influences (like infections and contaminants), and changes in lifestyle, such as heightened stress and altered diets. Cosentyx (secukinumab) supports individuals with autoimmune diseases by targeting and blocking interleukin-17A, a crucial cytokine in inflammation, which effectively lessens symptoms, enhances quality of life, and aids in managing conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. For example, data from Public Health Scotland, a national organization based in Scotland, indicated that in 2023, the Scottish Multiple Sclerosis Register (SMSR) registered 455 new MS diagnoses, as reported in August 2024. Consequently, the increasing occurrence of autoimmune diseases fuels the Cosentyx market.

Which Segment Classifications Shape The Cosentyx Drug Market?

The cosentyx drug market covered in this report is segmented –

1) By Indication: Hidradenitis suppurativa, Psoriatic arthritis, Ankylosing spondylitis, Plaque Psoriasis

2) By Route Of Administration: Subcutaneous injection, Intravenous infusion

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

How Are Trends Impacting The Cosentyx Drug Market?

Major companies operating in the cosentyx drug market are prioritizing the development of advanced therapies, such as biological treatment options, to address unmet medical needs, enhance treatment efficacy, and deliver targeted therapies for managing chronic autoimmune conditions, thereby solidifying their market position and serving an increasing patient population. Biologic treatments are sophisticated therapies derived from living organisms or their cells, specifically engineered to target components of the immune system, such as interleukin-17A, to modulate inflammatory responses and effectively treat autoimmune conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, secured FDA approval for Cosentyx (secukinumab) as the first new biologic treatment option for moderate to severe hidradenitis suppurativa (HS) in nearly a decade. This approval represents a significant advancement in the treatment landscape for HS, a chronic and often debilitating skin condition characterized by painful lumps that can lead to scarring and psychological distress.

Which Companies Are Expanding Their Footprint In The Cosentyx Drug Market?

Major companies operating in the cosentyx drug market are Novartis AG

Read the full cosentyx drug market report here:

https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report

Which Geographic Regions Are Influencing Demand In The Cosentyx Drug Market?

North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cosentyx Drug Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19891&type=smp

Browse Through More Reports Similar to the Global Cosentyx Drug Market 2026, By The Business Research Company

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795